- Home
- GRVY vs PBYI Comparison
GRVY vs PBYI Comparison
Compare GRVY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | PBYI |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.5M | 343.9M |
| IPO Year | 2005 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GRVY | PBYI |
|---|---|---|
| Price | $62.71 | $7.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.8K | ★ 256.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.54 | $3.03 |
| 52 Week High | $74.75 | $7.90 |
Technical Indicators
Market Signals| Indicator | GRVY | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 53.25 |
| Support Level | $62.97 | $7.09 |
| Resistance Level | $65.34 | $7.25 |
| Average True Range (ATR) | 2.05 | 0.33 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 44.50 | 50.79 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.